Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Addition of fulvestrant to endocrine treatment strategy evaluated
October 13th, 2005
The addition of fulvestrant to the endocrine treatment strategy was recently evaluated. According to recent research from England, "Fulvestrant, a new type of estrogen receptor antagonist with no agonist effects, is now licensed in the E.U. and U.S.A. for the treatment of postmenopausal women with hormone-sensitive advanced breast cancer following progression on prior antiestrogen therapy. Approval was based on data from two phase III trials that demonstrated fulvestrant was at least as effective as the third-generation aromatase inhibitor (AI) anastrozole as a second-line treatment for advanced breast cancer." "The third-generation AIs letrozole and...
Source: Women's Health Weekly (2005-10-13)
|
